Dr Rodriguez Otero on LINKER-SMM1

Experts explore the evolving treatment strategies for high-risk smoldering multiple myeloma, highlighting studies that show early intervention can improve patient outcomes.

A phase 2 study evaluates linvoseltamab's safety and efficacy in high-risk smoldering myeloma, focusing on response rates and MRD negativity.

Paula Rodriguez Otero, MD, PhD, discusses linvoseltamab's manageable safety profile in high-risk smoldering multiple myeloma, highlighting promising study results.

Paula Rodriguez Otero, MD, PhD, discusses promising results of linvoseltamab in high-risk smoldering multiple myeloma, highlighting its potential to prevent disease progression.

Experts explore innovative therapies for high-risk smoldering multiple myeloma, aiming to delay progression and enhance patient outcomes through early intervention.